Effects of fibrates on serum metabolic parameters

Current Medical Research and Opinion

Volumn 18, Issue 5, 2002, Pages 269-276

  Elisaf, M ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Ciprofibrate; Fenofibrate; Fibrates; Peroxisome proliferator activated receptor (PPAR ); Uricosuria

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN C3; CYCLOOXYGENASE 2; CYTOCHROME P450; FATTY ACID; FENOFIBRATE; FENOFIBRIC ACID; FIBRIC ACID DERIVATIVE; FIBRINOGEN; GAMMA GLUTAMYLTRANSFERASE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INDAPAMIDE; LIPOPROTEIN A; LOSARTAN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLASMINOGEN ACTIVATOR INHIBITOR 1; THIADIAZINE DERIVATIVE; THROMBOCYTE ACTIVATING FACTOR; TRIACYLGLYCEROL; UNINDEXED DRUG; URICOSURIC AGENT; VERY LOW DENSITY LIPOPROTEIN;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DIARRHEA; DRUG EFFECT; DRUG INDUCED DISEASE; DYSLIPIDEMIA; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HEADACHE; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; MONOCYTE; MORBIDITY; MORTALITY; NAUSEA; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; CARBOHYDRATES; CHOLESTEROL, HDL; CLINICAL TRIALS; CORONARY DISEASE; DRUG INTERACTIONS; HOMOCYSTEINE; HUMANS; HYPERLIPIDEMIAS; KIDNEY; LIPOPROTEINS; LIVER; TRIGLYCERIDES; URIC ACID;

EID: 0036040929     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079902125000516     Document Type: Article

References (90)

1. Fibrates, dyslipoproteinaemia and cardiovascular disease
2. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease
3. Treatment of dyslipidaemias in patients with established vascular disease: A revival of the fibrates
4. Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia
5. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia
6. Micronized fenofibrate
7. The impact of micronized fenofibrate on lipid subfractions and on reaching HDL-targets in 7,098 patients with dyslipidaemia
8. Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia
9. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia
10. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia
11. Effect of gemfibrozil treatment in hypercholesterolemia on low density lipoprotein (LDL) subclass distribution and LDL-cell interaction
12. i and dense LDL in type 2 diabetes. Impact of the degree of triglyceridemia
13. Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia
14. Bezafibrate: Treating hyperlipidemias as well as other cardiovascular risk factors
15. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: Response to ciprofibrate of lifestyle advance
16. Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia
17. Double-blind comparison of bezafibrate versus placebo in male volunteers with hyperlipoproteinemia
18. Effects of treatment of hypertriglyceridemia with gemfibrozil on serum lipoproteins and the transfer of cholesteryl ester from high density lipoproteins to low density lipoproteins
19. Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome
20. Postprandial lipoprotein metabolism in obese patients with moderate hypertriglyceridemia: Effect of gemfibrozil
21. Ciprofibrate - A profile
22. Efficacy and tolerability of etofibrate and gemfibrozil in combined hyperlipidaemia
23. Efficacy of ciprofibrate in primary type II and IV hyperlipidemia: The Italian multicenter study
24. Gemfibrozil reduces postprandial lipemia in non-insulindependent diabetes mellitus
25. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study
26. The use of fibrates and of statins in preventing atherosclerosis in diabetes
27. Lipid-lowering trial in diabetes
28. Diabetes: Statins, fibrates, or both?
29. The role of fibric acids in atherosclerosis
30. The PPARs: From orphan receptors to drug discovery
31. Modulation of lipoprotein production in hep G2 cells by fenofibrate and clofibrate
32. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene
33. Activation of human aortic smooth-muscle cells is inhibited by PPARγ but not by PPARα activators
34. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-II expression: A potential physiologic basis for their mode of action
35. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor
36. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male post infarction patients
37. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol
38. Primary-prevention trial with gemfibrozil in middle aged men with dyslipidemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease
39. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: Implications for treatment
40. Secondary prevention by raising HDL-cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study
41. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
42. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: A randomized controlled trial
43. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT)
44. Ciprofibrate therapy improves endothelial function and reduces postprandial and oxidative stress in type 2 diabetes mellitus
45. Peroxisome proliferator-activated receptor activators inhibit thrombin- induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway
46. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1
47. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells
48. Effect of ciprofibrate on CRP and fibrinogen levels
49. 2+-induced oxidative modification in vitro
50. Does micronized fenofibrate affect PAF-acetylhydrolase activity?
51. Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X
52. Effects of gemfibrozil on insulin sensitivity and on hemostatic variables in hypertriglyceridemic patients
53. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity
54. Gemfibrozil treatment of endogenous hypertriglyceridemia: Effect on insulin-mediated glucose disposal and plasma insulin concentrations
55. Effects of gemfibrozil therapy on glucose tolerance, insulin sensitivity and plasma plasminogen activator inhibitor activity in hypertriglyceridaemia
56. Insulin action and glucose metabolism are improved by gemfibrozil treatment in hypertriglyceridemic patients
57. Altering triglyceride concentration changes insulin-glucose relationship in hypertriglyceridemic patients: Double-blind study with gemfibrozil with implications for atherosclerosis
58. Current lipid-lowering strategies for the treatment of diabetic dyslipidemia. An integrated approach to therapy
59. A place for fibrinogen-lowering drugs in cardiovascular disease?
60. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha
61. PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages
62. PPARγ activators inhibit tissue factor expression and activity in human monocytes
63. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients
64. Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-1 in cultured cynomolgus monkey hepatocytes: Role of the peroxisome proliferator-activated receptor-alpha
65. Effects of two different fibric acid on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia
66. Effect of fenofibrate on serum uric acid levels
67. Management of hypertension and dyslipidemia in patients presenting with hyperuricemia: Case histories
68. The effects of the addition of micronized fenofibrate on uric acid metabolism in patients receiving indapamide
69. Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia
70. Serum uric acid levels: A useful but not absolute marker of compliance with fenofibrate treatment
71. Fibrate treatment can increase serum creatinine levels
72. Fibrate-induced increase in blood urea and creatinine: Is gemfibrozil the only innocuous agent?
73. Fibrate-induced increase in serum urea and creatinine levels
74. Altered hepatic eicosanoid concentrations in rats treated with the peroxisome proliferators ciprofibrate and perfluorodecanoic acid
75. Possible mechanisms of the fibrate-induced increase in serum creatinine
76. Effect of gemfibrozil on serum levels of prostacyclin and precursor fatty acids in hyperlipidemic patients with type 2 diabetes
77. Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia
78. Fenofibrate raises plasma homocysteine levels in the fasted and fed states
79. Effects of fenofibrate and gemfibrozil on plasma homocysteine
80. Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate
81. Statin + fibrate combination therapy. Fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease
82. Preliminary report: Ciprofibrate-fluvastatin combination therapy for dyslipidemia
83. Effects of combined bezafibrate-simvastatin appraised in healthy subjects
84. The effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities
85. A novel treatment for refractory primary biliary cirrhosis?
86. Micronised fenofibrate: A review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidemia
87. Fibrates: A review of important issues and recent findings
88. Fibrates and statins in the treatment of hyperlipidaemia: An appraisal of their efficacy and safety
89. Rhabdomyolysis due to combination therapy with cervistatin and gemfibrozil
90. Clinical pharmacokinetics of fibric and derivatives (fibrates)